- Home
- DMAC vs PSNL Comparison
DMAC vs PSNL Comparison
Compare DMAC & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- PSNL
- Stock Information
- Founded
- DMAC 2000
- PSNL 2011
- Country
- DMAC United States
- PSNL United States
- Employees
- DMAC N/A
- PSNL N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- PSNL Medical Specialities
- Sector
- DMAC Health Care
- PSNL Health Care
- Exchange
- DMAC Nasdaq
- PSNL Nasdaq
- Market Cap
- DMAC 274.1M
- PSNL 245.1M
- IPO Year
- DMAC N/A
- PSNL 2019
- Fundamental
- Price
- DMAC $4.82
- PSNL $6.12
- Analyst Decision
- DMAC Strong Buy
- PSNL Strong Buy
- Analyst Count
- DMAC 3
- PSNL 4
- Target Price
- DMAC $7.00
- PSNL $7.31
- AVG Volume (30 Days)
- DMAC 118.6K
- PSNL 1.2M
- Earning Date
- DMAC 11-13-2024
- PSNL 11-06-2024
- Dividend Yield
- DMAC N/A
- PSNL N/A
- EPS Growth
- DMAC N/A
- PSNL N/A
- EPS
- DMAC N/A
- PSNL N/A
- Revenue
- DMAC N/A
- PSNL $87,489,000.00
- Revenue This Year
- DMAC N/A
- PSNL $15.76
- Revenue Next Year
- DMAC N/A
- PSNL $4.02
- P/E Ratio
- DMAC N/A
- PSNL N/A
- Revenue Growth
- DMAC N/A
- PSNL 24.05
- 52 Week Low
- DMAC $2.14
- PSNL $1.12
- 52 Week High
- DMAC $6.41
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- DMAC 47.28
- PSNL 73.18
- Support Level
- DMAC $5.05
- PSNL $3.37
- Resistance Level
- DMAC $5.74
- PSNL $4.14
- Average True Range (ATR)
- DMAC 0.37
- PSNL 0.45
- MACD
- DMAC -0.08
- PSNL 0.25
- Stochastic Oscillator
- DMAC 28.10
- PSNL 95.07
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.